Canada markets closed

BriaCell Therapeutics Corp. (BCTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5400+0.1700 (+12.41%)
At close: 04:00PM EDT
1.4700 -0.07 (-4.55%)
After hours: 07:02PM EDT

BriaCell Therapeutics Corp.

Bellevue Centre
Suite 300 235 -15th Street
West Vancouver, BC V7T 2X1
604 921 1810

Full Time Employees16

Key Executives

NameTitlePayExercisedYear Born
Dr. William V. Williams M.D.CEO, President & Director785.3kN/A1955
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A.CFO & Corporate Secretary304.46kN/A1973
Dr. Miguel A. Lopez-Lago Ph.D.Chief Scientific Officer298.9kN/A1969
Dr. Giuseppe Del Priore M.D., M.P.H., MPHChief Medical Officer492.5kN/A1962
Dr. Charles Louis Wiseman FACP, M.D.Founder, Principal Research Advisor & Member of Scientific Advisory Board241.14kN/A1946
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Corporate Governance

BriaCell Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.